Sarepta Therapeutics

YTD

ALL

Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

CEO

Douglas S. Ingram

CEODouglas S. Ingram

Employees

1,372

Employees1,372

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1980

Founded1980

Employees

1,372

Employees1,372

SRPT Key Statistics

Market cap

3.94B

Market cap3.94B

Price-Earnings ratio

-15.54

Price-Earnings ratio-15.54

Dividend yield

—

Dividend yield—

Average volume

6.01M

Average volume6.01M

High today

$44.14

High today$44.14

Low today

$39.90

Low today$39.90

Open price

$41.04

Open price$41.04

Volume

8.43M

Volume8.43M

52 Week high

$173.25

52 Week high$173.25

52 Week low

$34.10

52 Week low$34.10

SRPT News

Simply Wall St 13h

Sarepta Therapeutics (NasdaqGS:SRPT) Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne

experienced a share price increase of 10% over the last week, possibly affected by significant advancements in its gene therapy for Duchenne muscular dystrophy...

Seeking Alpha 17h

Sarepta, Roche get U.K. feedback to lift clinical hold on Elevidys' Duchenne trial

Sarepta Therapeutics (NASDAQ:SRPT) and its partner Roche (OTCQX:RHHBY) received a 'go ahead' from the regulatory body in U.K. to lift clinical hold and continue...

TipRanks 18h

Sarepta announces MHRA says ENVISION dosing may continue as planned

Sarepta (SRPT) shared the following update related to Elevidys, the only approved gene therapy for patients with Duchenne muscular dystrophy. The company receiv...

Analyst ratings

81%

of 27 ratings

Buy

81.5%

Hold

18.5%

Sell

More SRPT News

TipRanks 3d

Positive Outlook for Sarepta Therapeutics Amid Elevidys Expansion and Strategic Collaborations

Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on May 16. Analyst Andrew Tsai from Jefferi...

People also own

Based on the portfolios of people who own SRPT. This list is generated using Robinhood data, and it’s not a recommendation.